Year-end Sale % OFF 
Abstract
HER2-positive accounts for 15-20% of breast cancers. Today the decision to escalate or de-escalate systemic therapy for early HER2-positive breast cancer is based primarily on traditional clinical factors, which are insufficient to reflect the molecular complexity and heterogeneity of HER2-positive breast cancer. Here we describe the development and validation of a new HER2RI assay, a model that combines expression data of 16 genes and clinical features to obtain risk values to predict the prognosis of early HER2-positive breast cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
